What Is Dermata Therapeutics, Inc. (DRMA) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Dermata Therapeutics, Inc.'s intrinsic value is estimated at a composite fair value of $1.99. While the stock appears modestly undervalued at $1.30 (implied upside of +52.7%), our analysis suggests a thinner margin of safety across 4 of 7 bullish models. Notably, First Chicago sees the most upside at +168.2% (fair value: $3.49), while ML-RIV is the most conservative at -93.2% ($0.09). The spread between these extremes — +261.4% — reveals how different analytical frameworks can reach starkly different conclusions.
What Do the Models Say About DRMA?
7 of 13 models are currently active for DRMA. Of these, 6 models suggest upside while 1 model suggests overvaluation. The Bayesian DCF estimates DRMA's intrinsic value at $1.30, implying +0.2% upside from the current price. See which stocks rank higher →
How Does DRMA Rank in Pharmaceutical Preparations?
Among 431 Pharmaceutical Preparations stocks, DRMA ranks #385 by Quality of Company score. CirclFi's QOC score of 3.1/10 evaluates 32 fundamental signals. A score of 3.1 signals below-average fundamentals.
See all Most Undervalued Pharmaceutical Preparations Stocks →
The Pharmaceutical Preparations sector introduces analytical considerations specific to healthcare company businesses. For Dermata Therapeutics, Inc., metrics like clinical trial success rate provide important context that general-purpose valuation models may underweight.
Is DRMA a Value Trap?
CirclFi's Value Trap algorithm assigns DRMA a score of 27/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
7 of 13 models are active for Dermata Therapeutics, Inc.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Deep Alpha Valuation Engine, Dermata Therapeutics, Inc. scores 3.1 out of 10 on our 32-signal quality assessment, a weak rating that exhibits fundamental weaknesses that warrant careful scrutiny. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.
The gap between the most bullish and bearish model spans +261.4% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every DRMA valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across DRMA's 7 active models, average confidence is 26%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad